PerkinElmer is working on an app that reports pathogenic or likely pathogenic ACMG-59 genetic variants, and NorthShore's app will report a prostate cancer risk score.
The single approach could be useful in some of the same areas where combinations of technologies have been implemented, such as AR-V7 testing in prostate cancer.
Physicians and prostate cancer patients are beginning to turn to genomic tests to guide treatment decisions, according to the Wall Street Journal.
Bringing together more than 1,000 prostate cancer exomes, researchers uncovered almost 100 significantly mutated genes, including drivers mutated in a fraction of tumors.
The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.
The companies will co-fund a new study of the 3DS technology, and MDxHealth will have the option to exclusively license the telomere-based test.
A Harvard genetics professor says that in spite of a history of misuse of genetics in discussions about race, scientists should not shy away from the conversation as long as it's done responsibly and scientifically.
The Fondazione Luigi Maria Monti - Istituto Dermopatico dell' Immacolata research hospital in Rome will perform SelectMDx testing locally.
The project allows prostate cancer patients to provide their de-identified clinical and genomic data to the research community.
NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.
Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.
A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.
In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.